ArticleAbdominal radiology (New York)2025
Evaluating extraprostatic extension of prostate cancer: pragmatic integration of MRI and PSMA-PET/CT.
Article in Abdominal radiology (New York), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Limited incremental prognostic value of pretreatment MRI andAbdominal radiology (New York) · 2026Article
- Addition of quantitative imaging parameters to visual analysis improves the accuracy of PSMA PET/CT for the local staging of primary prostate cancer.European journal of nuclear medicine and molecular imaging · 2026Article
- Imaging-based clinical decision tree enables risk stratification of extraprostatic extension before radical prostatectomy in prostate cancer patients.Insights into imaging · 2026Article
- Impact ofDiagnostics (Basel, Switzerland) · 2025Article
- Multimodal imaging deep learning model for predicting extraprostatic extension in prostate cancer using MpMRI and 18 F-PSMA-PET/CT.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo explore pragmatic approaches integrating MRI and PSMA-PET/CT for evaluating extraprostatic extension (EPE) of prostate cancer (PCa).
methodsConsecutive patients with newly-diagnosed PCa that underwent multiparametric MRI and PSMA-PET/CT, followed by radical prostatectomy in 2021-2024 were included. Imaging parameters assessed on both modalities were: size, length of capsular contact (LCC), Likert scales (MRI EPE grade/PSMA Likert scale), PI-RADS/PRIMARY scores, and SUV
results67 men (median age, 66 years) with EPE in 76.1% (51/67) were included. Area under ROC curves (AUC) were 0.61-0.82; MRI-based LCC yielded the highest AUC 0.82 (0.71-0.92) with cutoff of ≥ 1.7 cm. Integrated Likert scale (MRI EPE grade/PSMA Likert scale) showed sensitivity of 80.4% (41/51) and specificity of 31.3% (5/16). P score (PI-RADS/PRIMARY) demonstrated sensitivity of 31.3% (16/51) and specificity of 87.5% (14/16). Combining morphological MRI information with functional PSMA-PET/CT yielded sensitivity and specificity of 80.4% (41/51) and 81.2% (13/16), respectively, which demonstrated significantly higher sensitivity but non-significantly different specificity compared with MRI-based LCC alone (66.7% [34/51, p = 0.02] and 87.5% [14/16, p > 0.99]). This approach upgraded suspicion in 8 patients with LCC < 1.7 cm due to SUV
conclusionSeveral pragmatic approaches were explored for integrating MRI and PSMA-PET/CT to assess EPE in PCa. Combining morphological information from MRI and PSMA expression on PET/CT demonstrated good diagnostic performance and may be a simple pragmatic integrated method that can be used.
Indexed as
Identifiers
40252100What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.